BAC BV extends licence agreement with LFB Biotechnologies to produce protein for blood coagulation disorders

LFB Biotechnologies and BAC have been working together since 2008 to develop a custom-designed affinity ligand for the purification of the rhFVIIa product which LFB Biotechnologies developed in partnership with GTC Biotherapeutics.

BAC and LFB Biotechnologies have now entered into a license agreement to use the custom ligand in larger-scale production processes. Under the terms of the agreement, LFB Biotechnologies will have license to use BAC’s anti-FVIIa CaptureSelect ligand for the purification of rhFVIIa from transgenic animals expressing the recombinant protein during lactation. The CaptureSelect ligand has demonstrated the ability to achieve high purity in downstream processing, and has the potential to enhance the cost reduction benefits of the transgenic expression system developed by LFB Biotechnologies and GTC Biotherapeutics.

Laurens Sierkstra, CEO at BAC said: “Progressing from feasibility study to this scale-up stage is a critical time for both BAC and LFB Biotechnologies, which will be supported by the close and successful relationship that has developed between our two companies. Although the flexible nature of the CaptureSelect platform means that we can produce a ligand for any protein product, it has been extremely interesting to work with such a novel expression system.”